Hope And Hurdles For Sickle Cell Gene Therapy

(Posted on Tuesday, March 3, 2026)

Vertex’s CRISPR gene therapy Casgevy was supposed to mark the moment when sickle cell disease moved from lifelong crisis management to the possibility of a one‑time, near‑curative treatment. The rollout, however, has hit a surprisingly basic but formidable obstacle: centers cannot collect enough stem cells from the blood to manufacture the product for many patients. This bottleneck is slowing adoption and threatens Vertex’s early lead over rival therapies like bluebird bio’s Lyfgenia—a gene therapy that uses a different technique called a lentiviral vector, but which also faces its own safety challenges, including a boxed FDA warning about the risk of blood cancer.

Yet for those patients who complete the process and receive these drugs, the clinical results have been very strong: most have seen dramatic reductions in pain crises and improvements in blood health. The situation highlights both the promise of this new approach and the fragility of the infrastructure for complex cell and gene therapies.

What The Therapy Promised and How It Works

Sickle cell disease is an inherited blood disorder that causes red blood cells to become stiff and sickle-shaped, making them hard to carry oxygen and leading to painful episodes and organ damage. Standard treatments focus on easing pain, providing regular blood transfusions, or, in rare cases, performing bone marrow transplants. While these treatments help people live longer, they usually don’t cure the disease and can have serious side effects.

Casgevy works by changing some of a patient’s own blood stem cells so they make a special type of hemoglobin that doesn’t “sickle.” This helps prevent the pain and health complications associated with sickle cell disease. During therapy, stem cells are collected from the patient using apheresis—a process similar to blood donation, in which blood is withdrawn, stem cells are separated and the remaining blood is returned. This often requires several hours. Before the gene-edited cells can be infused, the patient must undergo intensive chemotherapy to clear their existing bone marrow. This “conditioning” step, necessary for the new cells to engraft, can cause severe side effects and requires a hospital stay. Afterward, the gene-edited cells are returned to the patient.

To make Casgevy, millions of healthy stem cells are needed from each patient. This often takes several tries. Many may need to go through multiple rounds of long, tiring cell collection sessions—sometimes four or more—spread out over weeks. For people already dealing with pain and health problems, this process can be exhausting and risky.

When patients complete the Casgevy process, the results are impressive. In studies, almost every patient who received the gene-edited cells had much higher levels of healthy hemoglobin and almost no severe pain crises for at least a year. Many patients stayed pain-free for several years after treatment.

Why Collecting Enough Cells Is So Hard

Biological factors complicate cell collection. Individuals with sickle cell disease often have damaged bone marrow and a history of transfusions and inflammation, which reduce stem cell reserves and responsiveness. Insufficient cell collection is a major barrier, partly due to the absence of standardized protocols. Collecting stem cells in people with sickle cell disease is also more dangerous, raising the risk of blood clots and even stroke. Because of this, many hospitals are not set up to safely perform the procedure for these patients.

These challenges are a big test for gene therapy as a whole. If even top hospitals struggle to collect enough cells, it will be even harder in parts of the world where sickle cell disease is most common and resources are limited. On top of infrastructure gaps, Casgevy’s list price of about $2.2 million per patient poses a significant access barrier—underscoring how cost and resource needs together create steep equity hurdles for those who might benefit most.

Gene Therapy’s Next Phase

These challenges are pushing research teams to discover better solutions. Some are working on new ways to make cell collection safer and easier. Others are trying to develop gene editing that can be done directly inside the body, which could one day remove the need to collect cells at all.

The launch of Casgevy shows that medical breakthroughs depend on everyday challenges—like getting enough stem cells from patients. For now, this limits how many people can get the treatment and opens the door for alternatives. Still, the science behind gene therapy is solid, and early results are promising. As hospitals and companies improve how they collect cells and as new techniques are developed, more people with sickle cell disease could benefit from these near-curative treatments in the future.